SIDA
-
Upload
daniela-ramirez -
Category
Health & Medicine
-
view
349 -
download
0
description
Transcript of SIDA
![Page 1: SIDA](https://reader033.fdocument.pub/reader033/viewer/2022060115/55792a18d8b42a9c578b510a/html5/thumbnails/1.jpg)
VIHPARASITOLOGÍA
Dr. Ricardo Tepach Coello
Daniela Yelitza Ramirez López
![Page 2: SIDA](https://reader033.fdocument.pub/reader033/viewer/2022060115/55792a18d8b42a9c578b510a/html5/thumbnails/2.jpg)
VIH Retroviridae
SIDA
![Page 3: SIDA](https://reader033.fdocument.pub/reader033/viewer/2022060115/55792a18d8b42a9c578b510a/html5/thumbnails/3.jpg)
• ARN monocatenario retrontranscritorio
• Diámetro de 80-100 nm
• LT CD4
![Page 4: SIDA](https://reader033.fdocument.pub/reader033/viewer/2022060115/55792a18d8b42a9c578b510a/html5/thumbnails/4.jpg)
VIH-1 VIH-2
![Page 5: SIDA](https://reader033.fdocument.pub/reader033/viewer/2022060115/55792a18d8b42a9c578b510a/html5/thumbnails/5.jpg)
![Page 6: SIDA](https://reader033.fdocument.pub/reader033/viewer/2022060115/55792a18d8b42a9c578b510a/html5/thumbnails/6.jpg)
EPIDEMIOLOGÍA
MUNDIAL2010-34 millones enfermos-1.8 millones muertos
NACIONAL2011-152 390 notificados-82.2% hombres 17.8% mujeres
1.5 con SIDA
68%- Distrito Federal
15.9%- México 11%- Veracruz 9.2%- Jalisco 7.4%- Puebla 4.2%- B. California 4.5%- Guerrero 4.3%- Chiapas 4.2%- Oaxaca 3.5%- Nuevo León 2.8%
![Page 7: SIDA](https://reader033.fdocument.pub/reader033/viewer/2022060115/55792a18d8b42a9c578b510a/html5/thumbnails/7.jpg)
TRANSMISIÓN
![Page 8: SIDA](https://reader033.fdocument.pub/reader033/viewer/2022060115/55792a18d8b42a9c578b510a/html5/thumbnails/8.jpg)
![Page 9: SIDA](https://reader033.fdocument.pub/reader033/viewer/2022060115/55792a18d8b42a9c578b510a/html5/thumbnails/9.jpg)
FASE AGUDA
Ausencia de tratamiento
Exposición a enfermedad oportunistas
![Page 10: SIDA](https://reader033.fdocument.pub/reader033/viewer/2022060115/55792a18d8b42a9c578b510a/html5/thumbnails/10.jpg)
Asintomáticos VS 40-90%
Malestar muscular
![Page 11: SIDA](https://reader033.fdocument.pub/reader033/viewer/2022060115/55792a18d8b42a9c578b510a/html5/thumbnails/11.jpg)
FASE CRÓNICAMultiplicación
1000-10 mil millones
Desarrollo 5 a 10 años
![Page 12: SIDA](https://reader033.fdocument.pub/reader033/viewer/2022060115/55792a18d8b42a9c578b510a/html5/thumbnails/12.jpg)
SIDA
ETAPA CRÍTICA
3 años
![Page 13: SIDA](https://reader033.fdocument.pub/reader033/viewer/2022060115/55792a18d8b42a9c578b510a/html5/thumbnails/13.jpg)
POBLACIÓN EN RIESGO
![Page 14: SIDA](https://reader033.fdocument.pub/reader033/viewer/2022060115/55792a18d8b42a9c578b510a/html5/thumbnails/14.jpg)
Se considera como una persona
seropositiva
•2 resultados de tamizaje de Ac +•Prueba suplementaria +
No se considera infectada
•1 prueba de tamizaje +•2 de tamizaje + pero suplementaria -
![Page 15: SIDA](https://reader033.fdocument.pub/reader033/viewer/2022060115/55792a18d8b42a9c578b510a/html5/thumbnails/15.jpg)
PRUEBAS DIAGNÓSTICAS
ELISA, Western blot.
![Page 16: SIDA](https://reader033.fdocument.pub/reader033/viewer/2022060115/55792a18d8b42a9c578b510a/html5/thumbnails/16.jpg)
TRATAMIENTO
Inhibidores de fusión a la membrana celular
Inhibidores de los correceptores Inhibidores de transcriptasa reversa análogos de nucleósidos y nucleótidos
Inhibidores de transcriptasa reversa no análogos de nucleósidos
Inhibidores de la integrasa Inhibidores de proteasa
![Page 17: SIDA](https://reader033.fdocument.pub/reader033/viewer/2022060115/55792a18d8b42a9c578b510a/html5/thumbnails/17.jpg)
VIHPARASITOLOGÍA
Dr. Ricardo Tepach Coello
Daniela Yelitza Ramirez López